Aviv Clinics.

What Aviv actually is

A focused product, not a general longevity practice. Aviv Clinics — flagship in The Villages, Florida, with sister sites in Be’er Ya’akov, Israel and Dubai — is built around one therapy: hyperbaric oxygen, delivered in Dr. Shai Efrati’s Hyperoxic-Hypoxic Paradox protocol over a three-month, 60-session course.

Efrati is the most-published HBOT researcher in the field. The protocol he runs at Aviv has its own clinical-trial dataset behind it. The research foundation, in our reading, is real.

The clinical product around the HBOT is what makes Aviv a longevity clinic rather than a hyperbaric centre: cognitive training during sessions, physical training between sessions, nutrition coaching, structured diagnostic intake, and follow-up out to five years. The frame is cognitive performance and age-related decline, not general longevity baselining.

What you get

The diagnostic intake is unusually deep on the cognitive axis. SPECT scans for cerebral perfusion mapping. A cognitive assessment battery that goes well beyond the typical executive workup. Amyloid beta and pTau biomarkers — relevant Alzheimer’s risk markers that most longevity clinics don’t run. Plus standard physical evaluation and biomarker testing.

For a patient with specific cognitive concerns — post-concussion recovery, age-related cognitive decline, family history of dementia — this is the workup that matches the question.

The treatment programme is the centre of gravity: 60+ HBOT sessions across roughly three months, in a multi-place chamber, with the proprietary protocol that alternates hyperoxic and hypoxic phases. Patients commute to The Villages (or stay locally) for the duration.

Where the evidence question lives

HBOT for clinical indications — post-stroke recovery, post-concussion, certain ulcer healing, decompression illness — has a robust literature behind it. HBOT for healthy-population longevity, the broader claim Aviv’s marketing sometimes implies, is less well-established.

Efrati’s clinical trials have shown promising signals on cognitive and biomarker outcomes in specific populations, and the publications are real. The gap between trial-grade outcomes in defined populations and cognitive performance enhancement in healthy adults is the gap a reader needs to understand before committing to the cheque.

We credit Aviv for publishing the research and being direct about the trial-grade framing in clinical conversation. We deduct points where the marketing copy outruns the published outcomes.

On the model

This is the cleanest example of the diagnose-then-treat conflict pattern in our directory. The diagnostic intake — at substantial cost — feeds directly into a 60+ session HBOT programme at the same clinic. There is no editorial separation between the workup that finds the indication and the practice that bills for the protocol that addresses it.

Aviv is, in our experience, not aggressive on this — clinicians who have decided a patient is not a candidate have said so. But the structural geometry is what it is, and the score reflects it.

Where Aviv is the right answer

For a specific reader profile, Aviv earns the visit.

The patient with diagnosed mild cognitive impairment, post-concussion symptoms, or significant family history of dementia, looking for a research-backed three-month protocol with structured measurement before and after. The diagnostic intake matches the question, the treatment has a published evidence base for that indication, and the multi-week commitment delivers what it claims.

For the reader looking for a general longevity baseline, Aviv is not it. The diagnostic spread is too cognitive-focused, and the treatment funnel is too narrow, to serve as a starting point.

The verdict

A specialist product, well-executed, with a structural conflict that we score honestly. If the cognitive question is yours, this is the directory’s strongest match. If it isn’t, the diagnostic-led generalist clinics (YEARS, Biograph, Human Longevity Inc.) are better starting points.

A clinic with one therapy and real research behind it is structurally different from a clinic with many therapies and thinner research behind any of them. Both can earn the price for the right patient.